Trevena Inc (NASDAQ:TRVN) — Market Cap & Net Worth
Market Cap & Net Worth: Trevena Inc (TRVN)
Trevena Inc (NASDAQ:TRVN) has a market capitalization of $345.52 ($345.52) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31990 globally and #6421 in its home market, demonstrating a -60.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Trevena Inc's stock price $0.00 by its total outstanding shares 863788 (863.79K). Also see Trevena Inc (TRVN) total assets for a full breakdown of the balance sheet.
Trevena Inc Market Cap History: 2015 to 2026
Trevena Inc's market capitalization history from 2015 to 2026. Data shows change from $5.67 Billion to $345.52 (-78.25% CAGR). Also see TRVN cash flow conversion for how efficiently the company converts equity into cash flow.
Trevena Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Trevena Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Trevena Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.99x
Trevena Inc's market cap is 4.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.67 Billion | $6.25 Million | -$50.53 Million | 906.98x | N/A |
| 2016 | $3.17 Billion | $3.75 Million | -$102.99 Million | 846.51x | N/A |
| 2018 | $232.14 Million | $5.73 Million | -$30.78 Million | 40.50x | N/A |
| 2019 | $453.97 Million | $31.00K | -$24.87 Million | 14644.34x | N/A |
| 2020 | $1.16 Billion | $3.07 Million | -$29.37 Million | 376.45x | N/A |
| 2021 | $314.47 Million | $567.00K | -$51.16 Million | 554.63x | N/A |
| 2022 | $30.88 Million | $-418.00K | -$53.67 Million | -73.88x | N/A |
| 2023 | $15.59 Million | $3.12 Million | -$40.29 Million | 4.99x | N/A |
Competitor Companies of TRVN by Market Capitalization
Companies near Trevena Inc in the global market cap rankings as of September 18, 2026. Review how tangible is Trevena Inc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Trevena Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Trevena Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Trevena Inc's market cap moved from $5.67 Billion to $ 345.52, with a yearly change of -78.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $345.52 | -96.67% |
| 2025 | $10.37K | -99.29% |
| 2024 | $1.46 Million | -90.64% |
| 2023 | $15.59 Million | -49.50% |
| 2022 | $30.88 Million | -90.18% |
| 2021 | $314.47 Million | -72.78% |
| 2020 | $1.16 Billion | +154.49% |
| 2019 | $453.97 Million | +95.56% |
| 2018 | $232.14 Million | -73.12% |
| 2017 | $863.79 Million | -72.79% |
| 2016 | $3.17 Billion | -44.00% |
| 2015 | $5.67 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Trevena Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $345.52 USD |
| MoneyControl | $345.52 USD |
| MarketWatch | $345.52 USD |
| marketcap.company | $345.52 USD |
| Reuters | $345.52 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Trevena Inc
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the… Read more